Omnitrope 5mg – Sandoz (Somatropin * 5mg/1.5ml x 5 vials )
Buy Omnitrope 5mg/1.5ml Online.Omnitrope (Somatropina) is a hormone that belongs to the group of peptides. It is secreted by the human pituitary under the action of a hypothalamic hormone called GH-RH. As its name says, its main function is to promote cell growth, regeneration and repair. It helps to activate the growth of bones, lean tissue, as well as the internal organs of the body. Thanks to it, the connective tissue constituting the tendinous, ligamentous and articular structures can repair itself and grow appropriately. But it is also involved in protein, carbohydrate, lipid, Vitamin and mineral metabolism. It is for its different virtues, that this compound has been used successfully to cure cases of dwarfism by deficiency in GH. It is even used clinically to treat adults deficient in growth hormone exceptionally well. This miraculous molecule is nowadays one of the rejuvenating treatments, not to mention its very interesting use in some cases of wide burns.
Posology and method of administration
Buy Omnitrope 5mg/1.5ml Online.Diagnosis and therapy with somatropin should be initiated and monitored by physicians who are
appropriately qualified and experienced in the diagnosis and management of patients with growth
The posology and administration schedule should be individualised.
Growth disturbance due to insufficient secretion of growth hormone in paediatric patients
Generally a dose of 0.025 – 0.035 mg/kg body weight per day or 0.7 – 1.0 mg/m2 body surface area per
day is recommended. Even higher doses have been used. Where childhood onset GHD persists into adolescence, treatment should be continued to achieve full
somatic development (e.g. body composition, bone mass). For monitoring, the attainment of a normal
peak bone mass defined as a T score > -1 (i.e. standardized to average adult peak bone mass measured
by dual energy X-ray absorptiometry taking into account sex and ethnicity) is one of the therapeutic
objectives during the transition period. For guidance on dosing see adult section below.
Prader-Willi syndrome, for improvement of growth and body composition in paediatric patients
Generally a dose of 0.035 mg/kg body weight per day or 1.0 mg/m2 body surface area per day is
recommended. Daily doses of 2.7 mg should not be exceeded. Treatment should not be used in
paediatric patients with a growth velocity less than 1 cm per year and near closure of epiphyses.
Growth disturbance due to Turner syndrome
A dose of 0.045 – 0.050 mg/kg body weight per day or 1.4 mg/m2 body surface area per day is
Growth disturbance in chronic renal insufficiency
A dose of 0.045 – 0.050 mg/kg body weight per day (1.4 mg/m2 body surface area per day) is
recommended. Higher doses may be needed if growth velocity is too low. A dose correction can be
needed after six months of treatment (see section 4.4).
Growth disturbance in short children/adolescents born small for gestational age (SGA)
A dose of 0.035 mg/kg body weight per day (1 mg/m2 body surface area per day) is usually
recommended until final height is reached (see section 5.1). Treatment should be discontinued after
the first year of treatment if the height velocity SDS is below + 1. Treatment should be discontinued if
height velocity is < 2 cm/year and, if confirmation is required, bone age is > 14 years (girls) or
> 16 years (boys), corresponding to closure of the epiphyseal growth plates. Dose recommendations in paediatric patients
Indication mg/kg body weight dose
mg/m² body surface
area dose per day
Growth hormone deficiency 0.025 – 0.035 0.7 – 1.0
Prader–Willi syndrome 0.035 1.0
Turner syndrome 0.045 – 0.050 1.4
Chronic renal insufficiency 0.045 – 0.050 1.4
Children/adolescents born small for
gestational age (SGA) 0.035 1.0
Growth hormone deficient adult patients
In patients who continue growth hormone therapy after childhood GHD, the recommended dose to
restart is 0.2 – 0.5 mg per day. The dose should be gradually increased or decreased according to
individual patient requirements as determined by the IGF-I concentration.